T-DM1, or Not T-DM1: That is the Question

Lisa holding Mittens; Misty sleeping.

Three weeks ago, Lisa had the first MRI scans of her brain since her neurosurgery. The report based on the MRI couldn’t have been better. The surgical site is healing nicely and there are no indications of new or progressing lesions.

She also had CT scans of her body and neck. The CT scans indicated that the disease in her lungs, lymph nodes, and bones remains stable. Unfortunately, the scan confirmed what Lisa had been feeling, a new mass in her poratid gland.

At that time, we agreed with her oncologist, that the best treatment option for her was to enroll her in a MGH Phase III clinical trial of a drug called T-DM1*. Since then Lisa has endured two trips to MGH and a barrage of medical tests in order to determine if she meets the eligibility requirements of the trial. The tests also set a baseline to track the efficacy of the treatment. Luckily, the doctors were able to use the recent MRIs and CT scans, but they needed a bone scan, an EKG, an echocardiogram, blood and other lab tests.

Although not required for the study, she also had a fine needle aspiration (FNA. What a lot of fun that was. Not! They only had to do it like six times!) of the lump in her parotid gland in order to determine what exactly is happening there. And it turns out that what is happening there is that her cancer has indeed metastasized to her parotid gland.

All the other test results came back within the required range except the echocardiogram which showed an ejection fraction** that was too low to qualify for the clinical trial. Her oncologist had her wait for a week and then retake the echo. The plan worked as her ejection fraction had risen just enough to qualify.

Today, we made a trip to our local oncologist’s office for a final set of blood tests. The results of which were faxed to the clinical trial people at MGH.

Assuming that the blood tests were within the required ranges, Lisa will be officially enrolled in the clinical trial. Once that happens she will be randomly selected for one of the two arms of the study. Two-thirds of the patients receive T-DM1 and the other third of the patients receive a standard treatment selected by their oncologist.

We will hear tomorrow which arm of the trial she is in. Until then, everyone think, “T-DM1, T-DM1,…”!

* Details of the T-DM1 clinical trial

** Ejection fraction = Volume % of blood pumped out of left ventricle per beat.

Advertisements
This entry was posted in T-DM1 & Systemic Treatment, Uncategorized. Bookmark the permalink.

6 Responses to T-DM1, or Not T-DM1: That is the Question

  1. I’m thinking T-DM1,…T-DM1…..Sending you my love, my prayers, I am in awe of you guys and your healing journey…Miss you all up at P.P. but John and I feel your presence even when we don’t see you. Love the photos, Scott, and your incredible blog, All my love, Judith

  2. Steve Lewers says:

    Sio and Scott,

    Katrina and I will simulaneously hold the phrase “T-DM1, T-DM1″ and our favorite mental halcyon scene in our minds each morning when we wake up. Let us know how quickly this does the trick, OK? We send our love, Steve

  3. Allen Hollander says:

    T-DM1, T-DM1 Hang in there. Good luck. Praying for you. Allen

  4. Laurie Christopher says:

    Tdm1, Tdm1…. Sounds like a great mantra…. Prayers for you Lisa!

  5. Deb says:

    The Well School is chanting….T-DM1, T-DM1

  6. L,
    Go for it…we can do it!!!!!
    Love
    M.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s